The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

The REMNANT study will evaluate whether treating minimal residual disease (MRD) relapse after first line treatment prolongs progression free survival and overall survival for myeloma patients versus treating relapse after first line treatment at progressive disease. To establish a homogenous group of MRD negative patients after first line treatment including autologous stem cell transplantation, patients are enrolled at diagnosis and treated with Norwegian standard of care first line treatment. MRD negative patients will move on to the randomized part.

NCT Number	NCT04513639
Lead Sponsor	Oslo University Hospital Collaborators: St. Olavs Hospital, Haukeland University Hospital, University Hospital of North Norway, University Hospital, Akershus, Helse Stavanger HF, Førde Central Hospital, Sorlandet Hospital HF, Nordlandssykehuset HF, The Hospital of Vestfold, Helse Nord-Trøndelag HF, Alesund Hospital, Sykehuset Ostfold
Conditions	Multiple Myeloma
Enrollment	176 participants
Start Date	2020-08-27
Primary Completion	2031-06-01 (estimated)
Study Completion	2032-06-01 (estimated)
Updated on ClinicalTrials.gov	2025-03-20